Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
October 18, 2023 14:36 ET
|
Muscular Dystrophy Association
New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of...
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
June 27, 2023 17:18 ET
|
Muscular Dystrophy Association
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the...
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
June 20, 2023 21:29 ET
|
Muscular Dystrophy Association
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod...
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
June 15, 2023 14:43 ET
|
Muscular Dystrophy Association
New York, June 15, 2023 (GLOBE NEWSWIRE) -- June 15, 2023 -- CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative...
MDA Launches Pinup & Roundup Campaigns at Thousands of Retail Partner Locations Nationwide to Fund Summer Camp for Kids and Young Adults 8-17 Living with Muscular Dystrophy & Related Neuromuscular Diseases
May 25, 2023 11:21 ET
|
Muscular Dystrophy Association
New York, May 25, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) today announced over 1,000 retail partner locations nationwide are participating with customer pinup, roundup or...
Muscular Dystrophy Association Announces Gene Therapy Support Network for Families Living with Neuromuscular Disease
May 22, 2023 14:48 ET
|
Muscular Dystrophy Association
New York, May 22, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) announced today the launch of the MDA Gene Therapy Support Network (GTx), ahead of a pending FDA approval for the...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 16, 2023 06:00 ET
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
Muscular Dystrophy Association Tribute Awards in Washington D.C. Honor Diana X. Bharucha-Goebel, M.D., R. Rodney Howell, M.D., Paul Robertson, Jeni Stepanek, Ph.D., Janet Woodcock, M.D.
May 11, 2023 11:55 ET
|
Muscular Dystrophy Association
New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) Tribute Awards will be held in Washington D.C. to honor: Diana X. Bharucha-Goebel, M.D., Associate Professor,...
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
April 25, 2023 15:52 ET
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...